Home
    • Plans Blog Contact
    Oncology Institute Inc logo

    Oncology Institute Inc

    TOI
    Last price US$4.98
    Market cap US$497.9m
    12M price change 36.44%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Universal Health Services IncUHS Industry peer DaVita HealthCare Partners IncDVA Industry peer CHEMED CORPCHE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Oncology Institute Inc Overview

    Industry: Medical Care Facilities

    Sector: Healthcare

    The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial servic Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Oncology Institute Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $147.4M (+41.2% YoY); EPS was -$0.02 (reported).

    Revenue $147.4M +41.2% YoY
    EPS -$0.02 reported
    Net loss -$2.5M from $19.6M
    Adjusted EBITDA $0 reported

    What changed

    • Revenue +41.2% YoY to $147.4M; EPS reported to -$0.02.
    • Net loss was -$2.5M (from $19.6M).

    Guidance / outlook

    The Company expects approximately $150 million in capitated revenue in 2026. For the second quarter of 2026, we anticipate Adjusted EBITDA of $(1) million to $1 million, reflecting seasonal improvement as deductibles are satisfied and continued ramp of our Florida delegated lives TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 8-K May 07, 2026 SEC filing 10-Q May 07, 2026 Earnings release PRESS RELEASE Mar 12, 2026 SEC filing FORM 8-K Mar 12, 2026 SEC filing 10-K Mar 12, 2026 SEC filing FORM 8-K Jan 12, 2026 SEC filing EXHIBIT 99.1 Jan 12, 2026 SEC filing 10-Q Nov 13, 2025 SEC filing FORM 8-K Nov 13, 2025 Earnings release EXHIBIT 99.1 Nov 13, 2025 SEC filing 10-Q Aug 13, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Oncology Institute Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

    Return on Equity

    Score 0.30/5
    Oncology Institute Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Oncology Ins... TOI US$497.9m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.19/5
    Oncology Institute Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Oncology Ins... TOI US$497.9m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

    Leverage

    Score 1.85/5
    Oncology Institute Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Oncology Ins... TOI US$497.9m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Oncology Institute Inc logo

    Oncology Institute Inc

    US$4.98

    US$497.9m

    -6.92%

    36.44%